Phase	phase	O	O	O	O
II	ii	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
vinorelbine	vinorelbine	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
metastatic	metastatic	O	O	O	O
squamous	squamous	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
esophageal	esophageal	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

European	european	O	O	O	O
Organization	organization	O	O	O	O
for	for	O	O	O	O
Research	research	O	O	O	O
and	and	O	O	O	O
Treatment	treatment	O	O	O	O
of	of	O	O	O	O
Cancer	cancer	O	DISEASE	OTHERS	I
Gastrointestinal	gastrointestinal	O	O	O	O
Treat	treat	O	O	O	O
Cancer	cancer	O	DISEASE	OTHERS	I
Cooperative	cooperative	O	O	O	O
Group	group	O	O	O	O
.	.	O	O	O	O
PURPOSE	purpose	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
and	and	O	O	O	O
toxic	toxic	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
vinorelbine	vinorelbine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
VNB	vnb	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
administered	administered	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
single	single	O	O	O	O
agent	agent	O	O	O	O
in	in	O	O	O	O
metastatic	metastatic	O	O	O	O
squamous	squamous	O	O	OTHERS	I
cell	cell	O	O	OTHERS	I
esophageal	esophageal	O	O	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O
PATIENTS	patients	O	O	O	O
AND	and	O	O	O	O
METHODS	methods	O	O	O	O
:	:	O	O	O	O
Forty-six	forty-six	O	O	O	O
eligible	eligible	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
measurable	measurable	O	O	O	O
lesions	lesions	O	O	O	O
were	were	O	O	O	O
included	included	O	O	O	O
and	and	O	O	O	O
were	were	O	O	O	O
stratified	stratified	O	O	O	O
according	according	O	O	O	O
to	to	O	O	O	O
previous	previous	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

Thirty	thirty	O	O	O	O
patients	patients	O	O	O	O
without	without	O	O	O	O
prior	prior	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
and	and	O	O	O	O
16	16	O	O	O	O
pretreated	pretreated	O	O	O	O
with	with	O	O	O	O
cisplatin-based	cisplatin-based	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
were	were	O	O	O	O
assessable	assessable	O	O	O	O
for	for	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
and	and	O	O	O	O
response	response	O	O	O	O
.	.	O	O	O	O

VNB	vnb	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
administered	administered	O	O	O	O
weekly	weekly	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
25-mg/m2	25-mg/m2	O	O	O	O
short	short	O	O	O	O
intravenous	intravenous	O	O	O	O
(	(	O	O	O	O
i.v	i.v	O	O	O	O
.	.	O	O	O	O
)	)	O	O	O	O
infusion	infusion	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Six	six	O	O	O	O
of	of	O	O	O	O
30	30	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
20	20	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
without	without	O	O	O	O
prior	prior	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
achieved	achieved	O	O	O	O
a	a	O	O	O	O
partial	partial	O	O	O	O
response	response	O	O	O	O
(	(	O	O	O	O
PR	pr	O	O	O	O
)	)	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
[	[	O	O	O	O
CI	ci	O	O	O	O
]	]	O	O	O	O
,	,	O	O	O	O
8	8	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
39	39	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
median	median	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
response	response	O	O	O	O
was	was	O	O	O	O
21	21	O	O	O	O
weeks	weeks	O	O	O	O
(	(	O	O	O	O
range	range	O	O	O	O
,	,	O	O	O	O
17	17	O	O	O	O
to	to	O	O	O	O
28	28	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

One	one	O	O	O	O
of	of	O	O	O	O
16	16	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
6	6	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
with	with	O	O	O	O
prior	prior	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
complete	complete	O	O	O	O
response	response	O	O	O	O
(	(	O	O	O	O
CR	cr	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
of	of	O	O	O	O
31	31	O	O	O	O
weeks	weeks	O	O	O	O
'	'	O	O	O	O
duration	duration	O	O	O	O
(	(	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
0	0	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
30	30	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
overall	overall	O	O	O	O
response	response	O	O	O	O
rate	rate	O	O	O	O
(	(	O	O	O	O
World	world	O	O	O	O
Health	health	O	O	O	O
Organization	organization	O	O	O	O
[	[	O	O	O	O
WHO	who	O	O	O	O
]	]	O	O	O	O
criteria	criteria	O	O	O	O
)	)	O	O	O	O
was	was	O	O	O	O
15	15	O	O	O	O
%	%	O	O	O	O
(	(	O	O	O	O
CR	cr	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
2	2	O	O	O	O
%	%	O	O	O	O
;	;	O	O	O	O
PR	pr	O	O	O	O
13	13	O	O	O	O
%	%	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
6	6	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
29	29	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
median	median	O	O	O	O
dose-intensity	dose-intensity	O	O	O	O
(	(	O	O	O	O
DI	di	O	O	OTHERS	I
)	)	O	O	O	O
was	was	O	O	O	O
20	20	O	O	O	O
mg/m2/wk	mg/m2/wk	O	O	O	O
.	.	O	O	O	O

VNB	vnb	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
and	and	O	O	O	O
zero	zero	O	O	O	O
instances	instances	O	O	O	O
of	of	O	O	O	O
WHO	who	O	O	O	O
grade	grade	O	O	O	O
4	4	O	O	O	O
nonhematologic	nonhematologic	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
.	.	O	O	O	O

At	at	O	O	O	O
least	least	O	O	O	O
one	one	O	O	O	O
episode	episode	O	O	O	O
of	of	O	O	O	O
grade	grade	O	O	O	O
3	3	O	O	O	O
or	or	O	O	O	O
4	4	O	O	O	O
granulocytopenia	granulocytopenia	O	O	OTHERS	I
was	was	O	O	O	O
seen	seen	O	O	O	O
in	in	O	O	O	O
59	59	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
grade	grade	O	O	O	O
2	2	O	O	O	O
or	or	O	O	O	O
3	3	O	O	O	O
infection	infection	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
in	in	O	O	O	O
16	16	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
no	no	O	O	O	O
toxic	toxic	O	O	O	O
deaths	deaths	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
.	.	O	O	O	O

Other	other	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
were	were	O	O	O	O
rare	rare	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
peripheral	peripheral	O	O	OTHERS	I
neurotoxicity	neurotoxicity	O	DISEASE	OTHERS	I
has	has	O	O	O	O
been	been	O	O	O	O
minor	minor	O	O	O	O
(	(	O	O	O	O
26	26	O	O	O	O
%	%	O	O	O	O
grade	grade	O	O	O	O
1	1	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
These	these	O	O	O	O
data	data	O	O	O	O
indicate	indicate	O	O	O	O
that	that	O	O	O	O
VNB	vnb	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
an	an	O	O	O	O
active	active	O	O	O	O
agent	agent	O	O	O	O
in	in	O	O	O	O
metastatic	metastatic	O	O	O	O
esophageal	esophageal	O	DISEASE	OTHERS	I
squamous	squamous	O	DISEASE	OTHERS	I
cell	cell	O	DISEASE	OTHERS	I
carcinoma	carcinoma	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Given	given	O	O	O	O
its	its	O	O	O	O
excellent	excellent	O	O	O	O
tolerance	tolerance	O	O	O	O
profile	profile	O	O	O	O
and	and	O	O	O	O
low	low	O	O	O	O
toxicity	toxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
further	further	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
VNB	vnb	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
combination	combination	O	O	O	O
therapy	therapy	O	O	O	O
is	is	O	O	O	O
warranted	warranted	O	O	O	O
.	.	O	O	O	O

